The changes would be immediately effective in countries like Columbia, South Korea, Peru and Panama, where FTAs are in the final stages of approval.
In a landmark judgment likely to benefit Indian generic drug manufacturers in a big way, the US Supreme Court has ruled against patenting of products with slight modifications.
The contract research and manufacturing services may soon replace generic drugs manufacturing as the preferred business option for Indian pharmaceutical industry, if growing revenues from CRAMS business is any indication.
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
The pace of privatisation of the Indian healthcare segment is expected to be the fastest in the coming years.
Over 30 domestic pharmaceutical companies, including Ranbaxy, Cipla, Nicholas Piramal, Zydus Cadila and Torrent, face a possible ban on the sale of the generic version of Merck's pain management drug in the Indian market.
Data from the Central Information Commission, the apex body that hears complaints regarding denial of information under RTI, shows that corporate houses are increasingly using RTI to extract information from public authorities.
Pfizer's blockbuster drug Viagra (sildenafil citrate), hitherto approved for use in treatment of erectile dysfunction, may soon acquire a new identity as a "life saving drug" in treating pulmonary arterial hypertension in children.
The venue of the battle by Swiss multinational Novartis AG against the rejection of its patent application for blockbuster cancer drug Gleevac will now shift to the Patent Appellate Board's office.
Australia has joined the UK, USA and Canada in warning its citizens against using unapproved traditional medicines from India and China.
Hetero is the only Indian partner of multinational drug major Roche Scientific for the manufacture and supply of the latter's patented drug, Tamilflu in developing countries.
Merck is all set to introduce three of its money-spinning drugs - Cosopt, Invanz and Pneuvax in India.
Pharmaceutical companies which increase prices of their medicines beyond 10 per cent in a year will face regulatory action.
The resultant price increase was the cause of a surprise upward variation in the "drug and medicines" segment of the weekly wholesale price index of the ministry of commerce and Industry last week, it is learnt.
With the bidding for the generics business of Merck set to begin from Monday, domestic pharmaceutical companies in the fray, Ranbaxy Laboratories and Dr Reddy's Laboratories, are unlikely to go for an all-out bidding war.
The decision has come in the wake of allegations of plagiarism against the Mashelkar panel report.
"The product technology is coming from DNDi. Cipla will manufacture and make the product available in southeast Asia and other parts of the world at affordable pre-agreed prices," Amar Lulla, joint managing director, Cipla, said.
The international health organisations, protesting against Swiss pharmaceutical major Novartis AG's legal challenge to provisions of the Indian Patent Act
Even as the domestic pharmaceutical industry is exploring new markets in Latin America and the Commonwealth of Independent States, exports to countries in Africa are declining.
Having cut eight deals last year, the $1.3 billion pharma major Ranbaxy probably has the sharpest negotiating skills in the business.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances